All News

janefingr.JPG

Systemic Sclerosis Future Therapies and Outcome Measures

d Jack Cush, MD

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder.

Read Article
injectable.jpg

High Dose Anakinra Effective in COVID-19

d Jack Cush, MD

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared to controls at day 21.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

The Nine Lives of Hydroxychloroquine (Updated)

d Martin J. Bergman, MD

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast - COVID Kids and Men (5.15.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
CDC Logo

CDC on Pediatric Multi-System Inflammatory Syndrome

d Jack Cush, MD

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Read Article
HSP071.jpg

Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease

d RheumNow

As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.

Read Article
Free read from Schett et al on COVID and increased proinflammatory cytokines - TNF, IL-1β, IL-6, IL-8, G-CSF ^ GM-CSF; & chemokines, such as MCP1, IP10 and MIP1α, are increased with COVID-19, with higher levels in those who are critically ill. https://t.co/My9UJ0cmPn

Links:

Dr. John Cush RheumNow ( View Tweet)

Praise and thanks should be bestowed upon our many Medical Residents working front-line on COVID-19 in the hospital. This NPR article aptly portrays their experiences and words. Bless them for smarts and dedication! https://t.co/NxBY7kAOSG

Links:

Dr. John Cush RheumNow ( View Tweet)

4 patients with refractory lupus panniculitis (LEP) (mean age 15 yrs) were successfully treated with rituximab, w/ a rapid and sustained RTX response https://t.co/GxmA9w89k3

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheums - Register for Tuesday Nite Rheumatology from Down Under - Dr. Peter Nash and Dr. Philip Robinson will discuss COVID-Rheum Registry and Rheumatology during COVID. Register here - https://t.co/PXJmUleQfw

Links:

Dr. John Cush RheumNow ( View Tweet)

Effect of Covid on Practice? Medscape survey 55% drop in revenue, 60% drop Patient Volume; 43,000 healthcare workers laid off in March 2020; 9% of practices have closed temporarily; 225% increase in remote patient engagements. https://t.co/LHeYA5pE29

Links:

Dr. John Cush RheumNow ( View Tweet)

Adaptive clinical trial design advocated for drug development for the coronavirus #COVID-19 https://t.co/jcEdlFQtXQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Grand News and much Deserved. Congrats Professor Shanmugam!! https://t.co/jUjEv9dQuM

Links:

Dr. John Cush RheumNow ( View Tweet)

We are prioritizing the review of new ANDAs for drugs in shortage, and we recently approved a generic application for hydroxychloroquine to increase availability for patients who depend on this drug. https://t.co/eKqXlpRRQl

Links:

Dr. Janet Woodcock DrWoodcockFDA ( View Tweet)

Please believe that the Coronavirus is not a hoax, COVID-19 is not a conspiracy. Your doubts, ideology and slick videos cant change nearly 100,000 Americans dying from COVID in 3 short months. Please be vigilant with Distance, washing and masks

Dr. John Cush RheumNow ( View Tweet)

FWIW, the Mahevas observational data and Tang et al RCT of 150 pts just published together in @bmj_latest 1. Read both as preprints, nice to see them in a respected peer reviewed journal 2. Neither support a benefit from HCQ in COVID-19 Both PDFs at https://t.co/Mbrq7bFHk0 https://t.co/rTpLnhGnkf

Links:

Mike Putman EBRheum ( View Tweet)
Study of 140 SLE pts shows 45–50% w/ IFN-I gene expression; all correlated w/ active skin & 2/6 w/ arthritis. IFN-induced Mx1 protein correlated with IFN-I score (P<0.0001); 25% showed high PMN expression assoc w/ fever, serositis, low WBC, steroid use. https://t.co/a3Fp3qdbkG

Links:

Dr. John Cush RheumNow ( View Tweet)

Secukinumab shown to work in 9/15 (67%) of refractory Behçet’s patients (mucosal and articular dz) by 3 mos - Retrospective study looked a complete or partial responders. #s increased to 86.7% at 6 months. Doses: either 150 or 300 mg qmonth https://t.co/a3Fp3qdbkG

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved OTC availability of Voltaren Gel - now called Voltaren Arthritis Pain: a topical NSAID, 1st approved by FDA in 2007. Indicated for the pain of osteoarthritis - It has not been effective in strains, sprains, bruises, sports injuries https://t.co/Tla75Bn4H0

Links:

Dr. John Cush RheumNow ( View Tweet)

BCG & COVID: 1) Israeli study shows BCG vaccination during childhood had no protective effect on getting COVID-19 infection later. 2) Bladder cancer pts on BCG therapy who get COVID infection, can safely take IL-6 or IL-1 inhibitors, Just not TNF inhib. https://t.co/TlOj6b8Taf

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×